With a market cap of $59.9 billion, Cencora, Inc. (COR) is a leading global pharmaceutical solutions organization dedicated to improving the lives of people and animals worldwide. By partnering with pharmaceutical innovators and healthcare providers, the company enables secure, reliable access to therapies and healthcare solutions while advancing healthier futures.
The Conshohocken, Pennsylvania-based company is slated to announce its fiscal Q3 2026 results before the market opens on Wednesday, Aug. 5. Ahead of the event, analysts forecast Cencora to report an adjusted EPS of $4.37, up 9.3% from $4 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.